Bendamustine Liquid Formulations for Long-Term Storage Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bendamustine exhibits rapid degradation upon reconstitution due to hydrolysis, leading to instability in liquid form, making it unsuitable for long-term storage and requiring inconvenient reconstitution of lyophilized powders.
Innovation Solution
Formulations containing bendamustine with pharmaceutically acceptable fluids like propylene glycol, polyethylene glycol, ethanol, benzyl alcohol, glycofurol, or DMSO, along with stabilizing agents such as chloride salts or antioxidants, enhance stability, reducing impurities to less than 5% after 15 months at 5-25°C.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If bendamustine is formulated as a lyophilized powder for reconstitution, then it exhibits good chemical stability, but it requires inconvenient reconstitution taking 15-30 mins and shows rapid degradation upon reconstitution
Solution Approach 1:
The patent applies preliminary action by pre-formulating bendamustine in liquid form with stabilizing agents and specific excipients before use. The formulation is prepared in advance with protective measures (pH adjustment, addition of stabilizing agents like polysorbates and cyclodextrins) to prevent degradation, eliminating the need for on-site reconstitution and ensuring immediate stability and efficacy.
2Ease of operation
If bendamustine is stored in liquid form, then it is ready to use, but it exhibits rapid degradation and is not suitable for long-term storage
Solution Approach 1:
The patent employs intermediary substances as stabilizing agents to protect bendamustine from degradation. Specific intermediaries include polysorbates (Tween 80), cyclodextrins (methylated and hydroxypropylated derivatives), and pH buffers that act as mediators between the drug and environmental factors, preventing hydrolysis and oxidation while maintaining drug stability during long-term storage.
Solution Approach 2:
The patent applies parameter changes by optimizing the formulation's pH, concentration, and composition to enhance stability. The formulation maintains pH within a specific range (7.0-9.0) and uses controlled concentrations of stabilizing agents and excipients to prevent degradation pathways, enabling long-term storage while maintaining readiness for use.
3Productivity
If bendamustine is reconstituted from lyophilized powder, then it can be administered, but it produces impurities and shows chemical instability within hours
Solution Approach 1:
The patent converts the harmful effect of water-induced degradation into a benefit by using water-soluble stabilizing agents and excipients that protect the drug during reconstitution and storage. The formulation transforms the potentially harmful interaction between water and bendamustine into a controlled environment where stabilizing agents prevent degradation, ensuring both administration readiness and chemical stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations provide long-term stability with low impurity levels, allowing for ready-to-use solutions that maintain effectiveness for at least 15 months to 2 years without reconstitution, suitable for clinical use.
Implementation Method 1
Bendamustine undergoes hydrolysis by direct substitution rather than an addition elimination process due to the presence of the highly labile aliphatic chlorine atoms
Data Source
AI summary
Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.